Cargando…
Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F
Owing to the prevalence of the JAK2V617F mutation in myeloproliferative neoplasms (MPNs), its constitutive activity, and ability to recapitulate the MPN phenotype in mouse models, JAK2V617F kinase is an attractive therapeutic target. We report the discovery and initial characterization of the orally...
Autores principales: | Ma, L, Clayton, J R, Walgren, R A, Zhao, B, Evans, R J, Smith, M C, Heinz-Taheny, K M, Kreklau, E L, Bloem, L, Pitou, C, Shen, W, Strelow, J M, Halstead, C, Rempala, M E, Parthasarathy, S, Gillig, J R, Heinz, L J, Pei, H, Wang, Y, Stancato, L F, Dowless, M S, Iversen, P W, Burkholder, T P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641321/ https://www.ncbi.nlm.nih.gov/pubmed/23584399 http://dx.doi.org/10.1038/bcj.2013.6 |
Ejemplares similares
-
Photoredox Catalysis in a
Complex Pharmaceutical Setting:
Toward the Preparation of JAK2 Inhibitor LY2784544
por: Douglas, James J., et al.
Publicado: (2014) -
Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies
por: Peng, Sheng-Bin, et al.
Publicado: (2016) -
LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
por: Vakana, Eliza, et al.
Publicado: (2016) -
Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
por: Chen, V. J., et al.
Publicado: (1998) -
LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys
por: Adams, Andrew C., et al.
Publicado: (2013)